Actively Recruiting
Bimatoprost as a Treatment for Graves' Orbitopathy
Led by Johns Hopkins University · Updated on 2025-07-17
3
Participants Needed
1
Research Sites
712 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease
CONDITIONS
Official Title
Bimatoprost as a Treatment for Graves' Orbitopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of Graves' Ophthalmopathy with Exophthalmos/Proptosis
You will not qualify if you...
- Active Graves Disease
- Currently pregnant
- Taking Steroids
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Washington
Seattle, Washington, United States, 98104
Actively Recruiting
Research Team
E
Emily Li, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here